How to Cite
Abstract
For the 83 patients with HPV16-cancer of the cervix (cervical cancer) I-III stages it was performed a comparative analysis of primary tumor response to therapy, the clinical outcome of the disease for 3-5 years after radical treatment and an evaluation of the possible contribution in these rates of the physical status of the virus. It was shown that total tumors regression in the early stages of the observation predominate in patients with «high-integrated» virus DNA (the degree of integration > 50%) of compared with a group of patients with episomal and «low-integrated» form of the virus, but in a distant periods (3-5 years) in the first group predominate an adverse outcome of disease. This pattern is true for tumors of stage I-III, and for less common — I-II stages. It is assumed that the integration of HPV16 DNA into the cellular genome may serve as an independent predictor of clinical outcome of cervical cancer.References
Куевда Д.А., Ермакова Н.В., Шипулина О.Ю. и др. Высокая вирусная нагрузка и интеграция ВПЧ в геном человека как молекулярные маркеры диспластических изменений шейки матки // Сб. трудов 6-ой всероссийской научно-практической конференцию. — М. 2007. — Т. III. — С. 130-132.
Calin GA, Sevignani C, Dumitru C et al. Human microRNA genesare frequently located at fragile sites and genomicregionsinvolved in cancers // Proc Natl Acad Sci USA. — 2004. — Vol. 101. — P. 2999-3004.
Calin GA, Groce GM. MicroRNAs and chromosomal abnormalities in cancer cells // Jncogene. — 2006. — Vol. 25. — P. 6202-6210.
Dabic MM, Nola M, Tomicic I. et al. Adenocarcinoma of uterine: prognostic significance of clinicopathologic parameters, flow cytometry analysis and HPV infection // Acta Obstet Gynecol Scand. — 2008. — Vol. 87. — P. 366-372.
Gammoh N, Isaacson E, Tomaic V. et al. Inhibition of HPV-16 E7 oncogenic activity by HPV-16 E2 // Oncogene. — 2009. — Vol. 28. — P. 2299-2304.
Hamid NA, Brown C, Gaston K. The regulation of cell proliferation by the papillomavirus early proteins // Cell Mol Life Sci. — 2009. — Vol. 66. — P 1700-1717.
Hampson L, El Said Abd el Hady, Moore JV. et al. The HPV 16 E6 and E7 proteins and the radiation resistance of cervical carcinoma // FASEB J. — 2001. — Vol. 15. — P. 1445-1463.
Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact // 2009. — J Clinical Oncol. — Vol. 27. — P. 5848-5856.
Kraus I, Driesch C, Vinokurova S et al. The majority of viral-cellular fusion transcripts in cervical carcinomas contrascribe cellular sequences of known or predicted genes // Cancer Res. — 2008. — Vol. 68. — P. 2514-2522.
Lindel K, Burri HU, Altermatt HJ. et al. Human papillomavirus status in advanced cervical cancer predictive and prognostic significance for curative radiation treatment // Int J Gynecol Cancer. — 2005. — Vol. 15. — P 278-284.
Lindel K, de Villers EM, Burri P et al. Impact of viral E2-status on outcome after radiotherapy for patients with human papilloma 16-positive cancer of the uterine cervix // Int J Radiat Oncol Biol Phys. — 2006. — Vol. 65. — P. 760-765.
Lindel K, Rieken S, Daffinger S. et al. The transcriptional regulator gene E2 of the Human Papillomavirus (HPV) 16 influences the radiosensitivity of cervical keratinocytes // Radiat Oncol. — 2012. — Vol. 7. — P. 187-197.
Liu ZG, Zhao LN, Liu YW. et al. Activation of Cdc2 Contributes to Apoptosis in HPV E6 Expressing Human Ke-ratinocytes in Response to Therapeutic Agents // J Mol Biol. — 2007. — Vol. 374. — P. 334-345.
Liu Z, Yang X, Li Z et al. CASZ1, a candidate tumor-supressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression // Cell Death Differ. — 2011. — Vol. 18. — P. 1174-1183.
Matovina M, Sabol I, Grubisic G et al. Identification of human papillomavirus type 16 integration sites in highgrade precancerous cervical lesions // Gynecol Oncol. — 2009. — Vol. 113. — P. 120-127.
Nambaru L, Meenakumari B, Swaminathan R et al. Prognostic Significance of HPV Physical Status and Integration Sites in Cervical Cancer // Asian Pacific J Cancer Prevent. — 2009. — Vol. 10. — P. 355-360.
Pang E, Delic NC, Hong A et al. Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6*1 // Int J Radiat Oncol Biol Phys. — 2011. — Vol. 79. — P 860-865.
Peter M, Rosty C, Couturier J et al. MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors // Oncogene. — 2006. — Vol. 25. — P. 5985-5993.
Schmitz M, Driesch C, Beer-Grondke K et al. Loss of gene function as a consequence of human papillomavirus DNA integration // Int.J.Cancer. — 2012. — Vol. 131. — P. E593-E602.
Schmitz M, Driesch C, Jansen L et al. Non-Random Integration of the HPV Genome in Cervical Cancer // PLoS one. — 2012. — Vol. 7. — P. e39632-e39641.
Thorland EC, Myers SL, Gostout BS et al. Commom fragile sites are preferential targets for HPV16 integrations in cervical tumors // Oncogene. — 2003. — Vol. 22. — P. 1223-1237.
Vernon S, Unger E, Miller D et al. // Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer // Int. J. Cancer (Pred. Oncol.). — 1997. — Vol. 74. — P. 50-56.
Wentzensen N, Vinokurova S, von Knebei Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract // Cancer Res. — 2004. — Vol.64. — P 3878-3884.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...